Probing marine brown macroalgal phlorotannins as antiviral candidate against SARS-CoV-2: molecular docking and dynamics simulation approachArticle Published on 2022-12-012022-11-15 Journal: Molecular diversity [Category] COVID19(2023년), SARS, 치료제, [키워드] 3CLpro antagonist Antiviral antiviral intervention approach AutoDock binding affinities binding affinity candidate Compound compounds COVID-19 COVID-19 therapeutics Cys145 deviation docking Drug discovery drug-likeness Efficacy evaluated GLN189 Glu166 immunostimulatory inhibit interaction site MD simulation molecular molecular docking Molecular docking and dynamics simulation over Phlorotannin polyphenol Probing RdRP reported SARS-CoV-2 SARS-CoV-2 replication SARS-CoV-2. selected target protein target proteins targets therapeutic Thr190 were assessed [DOI] 10.1007/s11030-022-10383-y PMC 바로가기
Folic acid: a potential inhibitor against SARS-CoV-2 nucleocapsid protein엽산: SARS-CoV-2 뉴클레오캡시드 단백질에 대한 잠재적 억제제Article Published on 2022-12-012022-09-11 Journal: Pharmaceutical Biology [Category] COVID19(2023년), SARS, 유전자 메커니즘, 치료법, [키워드] analysed Analysis antagonist antiviral effects antivirus association cellular Chinese Chinese medicine Compound Concentration coronavirus disease Coronavirus disease 2019 COVID-19 Data analysis docking drug target experiment Folic acid Genes global pandemic Host hub genes identify inhibit inhibition inhibitor involved material mCherry mCherry expression mechanism molecular molecular docking network pharmacology Network pharmacology. Nucleocapsid phosphoprotein Phosphoprotein Protein Regulatory RNA interference RNAi SARS-CoV-2 SARS-CoV-2 N SARS-CoV-2 nucleocapsid screened shown target targets therapeutic target Traditional Traditional Chinese medicine virus [DOI] 10.1080/13880209.2022.2063341 PMC 바로가기 [Article Type] Article
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimodArticle Published on 2022-09-012022-11-15 Journal: Journal of neurology, neurosurgery, and psychiatry [Category] COVID19(2023년), SARS, 진단, [키워드] absence Acetate Alter analysed antagonist approved Autoimmune diseases B cell B cells booster booster vaccinations CD4 Cellular immune response clinical neurology elicit elicited fumarate functional immune response healthy individual homologous humoral humoral immune response IgG Immune cell immunogenic immunology Infection Infectious diseases investigated lack Measures mRNA mRNA vaccination mRNA vaccine multiple sclerosis multiple sclerosis. Neutralising activity Patient patients Peripheral blood prospective cohort study Protective receiving receptor Receptor binding reduced risk SARS-CoV-2 serum severe COVID-19 severe SARS-CoV-2 stability T cell T cell response T cell responses therapy these cell Treatment vaccination Vaccinations vaccine-specific antibodies [DOI] 10.1136/jnnp-2022-329395 PMC 바로가기
Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative GroupCOVID-19 폐렴이 있는 위독한 성인 환자에서 인터루킨-6 수용체 길항제의 효과: CORIMUNO-19 공동 그룹의 2건의 무작위 대조 시험Article Published on 2022-08-102022-09-11 Journal: The European Respiratory Journal [Category] Fulltext, SARS, 임상, [키워드] 95% CI antagonist anti-IL-6 receptor assigned Bayesian clinical trials clinically controlled clinical trials coronavirus disease Coronavirus disease 2019 COVID-19 credible interval CrI Critically ill Critically ill patient critically ill patients determine Effect events group hazard ratio IMPROVE indicated interleukin-6 receptor intravenously investigator-initiated mechanical ventilation median multicentre NIV Noninvasive ventilation not need numbers of patient Open-label outcome Patient patients with COVID-19 Pneumonia posterior probability randomised randomised controlled randomised controlled trial Randomly receive receptor risk of death SARI sarilumab significantly TCZ TOCI Tocilizumab Trial usual care with COVID-19 [DOI] 10.1183/13993003.02523-2021 PMC 바로가기 [Article Type] Article
Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19COVID-19 치료를 위한 히스타민 H2 수용체 길항제의 용도 변경을 위한 분자 기반Article Published on 2022-08-012022-09-11 Journal: Journal of biomolecular structure & dynamics [Category] Coronavirus, 신약개발, 유전자 메커니즘, [키워드] activities Analysis antagonist binding affinity carried Cimetidine complex coronavirus COVID-19 determine docking effective Efficacy Famotidine gene target high stability Histamine Ligand mechanism mechanism of action molecular basis molecular docking molecular docking. molecular dynamic simulation molecular dynamics Molecular dynamics simulation Nizatidine non-structural protein non-structural proteins Novel coronavirus Nsp3 Nsp7 Nsp9 Nsps Potential treatment preliminary report Ranitidine Result selected stability targets treat Treatment viral replication was performed [DOI] 10.1080/07391102.2021.1873191 PMC 바로가기 [Article Type] Article
Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19비스테로이드성 소염제 및 기타 에이코사노이드 경로 조절제가 항바이러스 및 알레르기 반응에 미치는 영향: COVID-19 시대의 에이코사노이드 합의 보고서에 대한 EAACI 태스크포스Article Published on 2022-08-012022-09-11 Journal: Allergy [Category] COVID19(2023년), SARS, 치료제, [키워드] allergic allergic diseases allergic inflammation allergy analgesic effect antagonist Anti-inflammatory anti-inflammatory drug Antipyretic Antiviral applied Asthma Biologicals biologicals. cannabinoids chronic inflammatory disease Consensus COVID-19 COVID-19 treatment Effect eicosanoid General population Horizon identify Inflammation Inflammatory diseases Interaction knowledge leukotriene leukotriene receptor antagonist leukotriene receptor antagonists LTRA mechanism mechanism of action medication medications NERD non-steroidal anti-inflammatory drug Non-steroidal anti-inflammatory drugs NSAID NSAIDS pandemic of COVID-19 pathway Pathways predict prostaglandin prostaglandin D2 Research Respiratory disease respiratory infections response SARS-CoV-2 selectivity Symptom therapy Treatment unmet need viral infection viral infections [DOI] 10.1111/all.15258 PMC 바로가기 [Article Type] Article
The effect of reparixin on survival in patients at high risk for in-hospital mortality: a meta-analysis of randomized trials병원 내 사망 위험이 높은 환자의 생존에 대한 레파릭신의 효과: 무작위 시험의 메타 분석Meta-Analysis Published on 2022-07-252022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 임상, [키워드] 95% confidence interval addition all-cause mortality antagonist anti-inflammatory drug Anti-inflammatory drugs article CENTRAL Chemokine receptor comparator control group Controlled controlled trials COVID-19 Critical Critical care critical care. CXCL-8 CXCL8 CXCR1 CXCR2 CXCR2 antagonist heterogeneity high risk identify IL-8 In-hospital in-hospital mortality include independent Infection inhibitor Intensive intensive & involved Meta-analysis no difference Odds ratio P -value Patient patients performed Pneumonia Randomized controlled trial Randomized controlled trials randomized trial randomized trials RCT RCTs receptor receptors Reparixin risk of bia risk of infection RoB 2 SARS-CoV-2 SARS-COV-2 infection screened searched Sepsis shown significantly lower suggested survival Treatment trials two groups was used [DOI] 10.3389/fimmu.2022.932251 PMC 바로가기 [Article Type] Meta-Analysis
Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis코로나19로 입원한 환자에서 토실리주맙, 사릴루맙, 28일 후 모든 원인 사망률 사이의 연관성: 네트워크 메타 분석Meta-Analysis Published on 2022-07-082022-09-11 Journal: PLoS ONE [Category] meta-analysis, 임상, 진단, [키워드] 28-day mortality all-cause mortality antagonist association choice clinician Consistency Corticosteroid Corticosteroids COVID-19 patient deaths demonstrated dependent on Effect eligible patient Evidence hospitalised patient Hospitalised patients in-hospital mortality inconsistency initiated interleukin-6 interleukin-6 receptor invasive ventilation Meta-analysis Network meta-analysis Non-invasive not dependent Odds ratio Odds ratios P-value Patient Placebo randomisation randomised randomised comparison receiving receptor antagonist REMAP-CAP REMAP-CAP trial sarilumab Tocilizumab Trial usual care Ventilation with COVID-19 [DOI] 10.1371/journal.pone.0270668 PMC 바로가기 [Article Type] Meta-Analysis
Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease종양 괴사 인자-α 길항제의 사용은 염증성 장 질환이 있는 백신 접종 환자에서 SARS-CoV-2에 대한 약화된 IgG 항체 반응과 관련이 있습니다Observational Study Published on 2022-07-052022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] Against age antagonist antagonists anti-SARS-CoV-2 antibody anti-SARS-CoV-2 vaccination antibody Antibody concentrations Antibody titer Antibody titers Biologicals Blood blood sampling bowel Characteristics clinical Clinical characteristics Combination completion Concentration COVID-19 Crohn's disease defined demonstrated detectable disease Effect elapsed geometric geometric mean IBD IgG IgG antibodies IgG antibody IgG antibody titer IgG antibody titers immune response immunoassay immunomodulating Immunosuppressive medication immunosuppressive medications increased risk independent independent of Inflammatory Inflammatory bowel disease medication Microparticle monotherapy Most patients mRNA mRNA vaccines mRNA-based vaccine mRNA-based vaccines Multivariable models Patient patient age patients patients treated prospective observational cohort quantitative determination RBD receive receiving Receptor-binding domain regimen response S1 subunit sampling SARS-CoV-2 SARS-COV-2 infection Seroconversion serological response significantly lower Spike protein the receptor-binding domain the S1 subunit the spike protein titer TNF-α-antagonists treated Treatment Tumor ulcerative colitis vaccination vaccination. Vaccine vector was used were measured were recorded [DOI] 10.3389/fimmu.2022.920333 PMC 바로가기 [Article Type] Observational Study
A Case Report of Tolvaptan Therapy for ADPKD Patients With COVID-19. The Need for Appropriate Counselling for Temporary Drug DiscontinuationArticle Published on 2022-07-012022-11-16 Journal: In vivo (Athens, Greece) [Category] COVID19(2023년), SARS, 치료기술, [키워드] acute kidney Acute kidney injury acute respiratory syndrome antagonist Appropriate autosomal dominant Case report cause counseling COVID-19 disease drug Elevation events indicated Infection liver enzyme male management mechanism of action occur pandemic Patient polycystic kidney disease polycystic kidney disease. Polydipsia progression receiving receptor renal report risk Safe SARS-CoV-2 SARS-COV-2 infection Side effect Side effects susceptibility symptomatic symptoms appeared temporary the patient therapy Tolvaptan treated Treatment Withdrawal [DOI] 10.21873/invivo.12924 PMC 바로가기